February 26, 2021

On OptimizeRX

 The Fool and TipRanks are bullish on OptimizeRX.  This is a small company with a valuation of under $1billion that has room to run.   

2 SPACs to Buy Right Now

 The Fool highlights two SPACs to buy:  IPOE and GHVI. 

February 22, 2021

Looking at Guardant Health

 The Fool looks at Guardant Health, which they have pegged as the leader in liquid biopsies.  They have several products on the market and will launch additional products this year. 

Waiting for Marqueta to go Public

One Fool is waiting for Marqueta to go public, which may happen around April.  He explains why it is a top IPO stock to look forward to.  

February 3, 2021

My Top Stock to Own for the Next 10 Years

 CareTrust REIT is this Fool's top stock to own for the next 10 years. 

February 1, 2021

On Vive Medical

 

This company’s products are very much in demand from women. Viveve Medical Inc. (NASDAQ: VIVE) designs, develops, manufactures and markets medical devices for the noninvasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation and stress urinary incontinence.

The Viveve System includes a radio frequency generator, reusable hand piece and treatment tip, as well as cryogen canister and other consumable components. The company markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East and Latin America.

The noninvasive, endovaginal Viveve system has been cleared and is marketed (by distribution partners) in more than 50 countries for a variety of noninvasive female health indications. The system also gained FDA clearance in late 2016, but only with a general surgical label. As of the end of third quarter 2020, the company had an installed base of 479 systems in the United States and 386 internationally.

Alliance Global has set a giant $10.75 target price. That compares with the much higher consensus target of $22. The stock has traded near $3.50 recently.